Induction of translational readthrough is a potential therapeutic strategy for nonsense mutant TP53-carrying tumors upon diagnosis, or for prevention of tumors in cancer-prone individuals such as LFS family members carrying an inherited TP53 nonsense mutation. The gene discussed is TP53; the disease is cancer.